Thinzar joined Dr. Todd Brusko’s Laboratory in 2019 to oversee the lab’s administrative and operational needs and overall maintenance in order to achieve optimal performance in quality and efficiency.
Thinzar earned her Bachelor of Science in Biological Sciences and completed her Master of Science degree specializing in Biotechnology Management from the University of Maryland.
Thinzar was employed at NIH in Bethesda, Maryland and at NCI in Fort Deterick, Maryland from 2008 to 2014. During her employment as a government contractor, Thinzar was involved in both in-vivo and in-vitro experiments that utilized 60 different human tumor cell lines to identify and characterize novel compounds, both synthetic and purified natural products, with growth inhibition or killing of tumor cell lines.
In late 2014, Thinzar joined the operation team at AstraZeneca/Medimmune Biologics Manufacturing Center in Frederick, Maryland. From 2014 to 2019, Thinzar supported the production of innovative new treatments such as Imfinzi (durvalumab) and Fasenra (benralizumab) through scientific leadership and multi-project management within the company’s cross-functional departments, as well as the FDA and international regulatory agencies.
Thinzar is a certified Six Sigma Yellow Belt with expertise in process variable mapping, failure mode effect analysis, lean management and waste reduction, and statistics and graphical analysis. In addition to her experience in successfully implementing operational excellence strategies in big pharma, she is a longtime advocator for empowering women both in the workplace and as individuals. She currently holds a position as a board chair in the Association for Academic Women at the University of Florida.